

Appl. No. 10/763,451
Amtd. Dated January 24, 2005
Reply to Office action of November 15, 2004

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Cancelled).

Claims 2-54 (Previously Cancelled).

Claim 55 (Previously Presented). A compound of the formula:



or a pharmaceutically acceptable salt of said compound, in which:

W is -O-,

R¹ is located at the 3-position and is selected from methyl, bromo, or chloro,

R² is located at the 5-position and is selected from methyl, bromo, or chloro,

R³ is located at the 2' position and is represented by hydrogen,

R⁴ is located at the 3' position and is represented by -C(R¹⁴)(R¹⁵)(R¹⁶),

R⁵ is located at the 4' position and is represented by hydroxy or methoxy,

R⁶ is located at the 5' position and is represented by hydrogen,

R⁷ is hydrogen,

R⁸ is hydrogen,

R¹⁴ is hydrogen, or -(C₁-C₆) alkyl,

Appl. No. 10/763,451
Amdt. Dated January 24, 2005
Reply to Office action of November 15, 2004

R^{15} is hydrogen or $-(C_1-C_8)$ alkyl,

R^{16} is $-(C_0-C_6)$ alkyl-aryl,

aryl is (a) phenyl optionally substituted with one or more substituents independently selected from Group Z; (b) naphthyl optionally substituted with one, or more substituents independently selected from Group Z or (c) biphenyl optionally substituted with one or more substituents independently selected from Group Z, and;

Group Z, for each occurrence, is independently selected from the group consisting of (a) hydrogen, (b) halogen, (c) trifluoromethyl, (d) hydroxy, (e) $-OCF_3$, (f) $-CN$, (g) $-NO_2$, and (h) $-(C_1-C_6)$ alkyl.

Claim 56 (Previously Presented). A compound according to claim 55 in which R^1 and R^2 are each methyl.

Claim 57 (Previously Presented) A compound according to claim 55 in which R^5 is hydroxy.

Claim 58 (Currently Amended). A compound according to claim 55 in which R^{16} is (C_0C_1) alkyl-aryl.

Claim 58-59 (Currently Amended) A compound according to claim 58 in which aryl is phenyl, optionally substituted with one or more substituents independently selected from Group Z.

Claim 59-60 (Currently Amended) A compound according to claim 55 selected from the group consisting of:

- i) 2-{3-chloro-4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-2H [1,2,4]triazine-3,5-dione;
- ii) 2-{4-[3-(4-fluoro-benzyl)-4-methoxy-phenoxy]-3,5-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione;
- iii) 2-(4-{3-[(4-fluoro-phenyl)-hydroxy-methyl]-4-hydroxy-phenoxy}-3,5-dimethyl-phenyl)-2H-[1,2,4]triazine-3,5-dione;
- iv) 2-{4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione

Appl. No. 10/763,451
Amdt. Dated January 24, 2005
Reply to Office action of November 15, 2004

- v) 2-{3,5-dichloro-4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione, and;
- vi) 2-{3,5-dibromo-4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione

Claim 60-61 (Currently Amended). A pharmaceutical composition comprising an effective amount of a compound of claim 1-55 or a pharmaceutically acceptable salt of said compound, in admixture with a pharmaceutically acceptable carrier.

Claim 61-62 (Currently Amended). 2-{4-[3-(4-Fluoro-benzyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione, or a pharmaceutically acceptable salt of said compound.

Claim 62-63 (Currently Amended). A topical pharmaceutical composition comprising an effective amount of a compound of claim 61-62, in admixture with a pharmaceutically acceptable topical carrier.